Yeah, I have to say I hadn't fully understood the need for the 2nd / 3rd wave vaccines. I understood that not everyone will be able to get a vaccine in 2021 even if all three of the vaccine providers get approval, but I didn't understand quite how much. If you combine together Pfizer's
1.3bn, Moderna's
500m - 1bn and Astra Zeneca's
3bn, best case scenario you'll have 5.3bn manufactured, with
5-20% of that potentially spoiling and double doses bringing you to around possible vaccination for 2.2-2.5bn people. So a little over a third of the adult population, and Fauci confirmed child vaccination is part of the plan, so a quarter of the total population.
The thing I'm not clear on is whether the time and resources we invest in creating these new vaccines couldn't just be reallocated to improving manufacturing and distribution for the three current vaccines. Moderna have said they can do 500m, up to 1bn. Clearly there's room to improve capacity with their current plans. Lonza said they can produce 400m from 4 production plants in the US and Switzerland, and while they could set up another plant or two in Switzerland and Singapore, they aren't planning to.
It's an expensive business but surely the 100s of vaccine trials come with significant expenses too, and much of the expertise being applied there could be better used trying to solve the production challenges for vaccines that we already know work?
The other part of it is that the human challenge trials are happening in the UK in January, when they're aiming for 90 people. Giving the expected spike in infection post-Christmas, and the fact that your chances of getting covid right now are about
1 in 80, it's not clear to me that they wouldn't just be better off doing a normal trial of 7,000 people? I get that there are additional benefits to the intense monitoring but it just seems like the cost / benefit ratio has shifted a lot since they first planned it.